Literature DB >> 14742302

Latency and persistence of respiratory syncytial virus despite T cell immunity.

Jurgen Schwarze1, Diarmund R O'Donnell, Angela Rohwedder, Peter J M Openshaw.   

Abstract

Respiratory syncytial virus (RSV) causes bronchiolitis in infants, which is associated with recurrent wheezing in later childhood. There is mounting evidence that the virus becomes latent or persists in vivo, but little is known about the mechanisms of its latency, persistence, and immune evasion. We therefore infected BALB/c mice intranasally with human RSV, analyzed sequential tissue samples by direct culture and polymerase chain reaction for viral and messenger RNA, and monitored antiviral immune responses. Virus could not be detected in bronchoalveolar lavage samples beyond Day 14, but viral genomic and messenger RNA was present in lung homogenates for 100 days or more; combined depletion of CD4 and CD8 T cells allowed infective virus to be recovered. Neutralizing antibody and memory cytotoxic T cell responses were intact in mice with latent infections, and latent viral genome contained an authentic nonmutated M2 82-91 K(d) cytotoxic T lymphocyte epitope. A mutation of this epitope, detected in one clone, did not assist evasion. We suggest that RSV latency depends on persistence in privileged sites rather than on viral mutation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742302     DOI: 10.1164/rccm.200308-1203OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  68 in total

1.  Respiratory syncytial virus infection in human bone marrow stromal cells.

Authors:  Fariba Rezaee; Laura F Gibson; Debbie Piktel; Sreekumar Othumpangat; Giovanni Piedimonte
Journal:  Am J Respir Cell Mol Biol       Date:  2010-10-22       Impact factor: 6.914

2.  Rapid Evolution of the CD8+ TCR Repertoire in Neonatal Mice.

Authors:  Alison J Carey; Donald T Gracias; Jillian L Thayer; Alina C Boesteanu; Ogan K Kumova; Yvonne M Mueller; Jennifer L Hope; Joseph A Fraietta; David B H van Zessen; Peter D Katsikis
Journal:  J Immunol       Date:  2016-02-12       Impact factor: 5.422

3.  Acute and Chronic Airway Disease After Human Respiratory Syncytial Virus Infection in Cotton Rats (Sigmodon hispidus).

Authors:  Jessica L Grieves; Zhiwei Yin; Russell K Durbin; Joan E Durbin
Journal:  Comp Med       Date:  2015-08       Impact factor: 0.982

4.  The fusion protein of respiratory syncytial virus triggers p53-dependent apoptosis.

Authors:  Julia Eckardt-Michel; Markus Lorek; Diane Baxmann; Thomas Grunwald; Günther M Keil; Gert Zimmer
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

Review 5.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

6.  Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children.

Authors:  Chadi M El Saleeby; Andy J Bush; Lisa M Harrison; Jody A Aitken; John P Devincenzo
Journal:  J Infect Dis       Date:  2011-10-01       Impact factor: 5.226

7.  Respiratory syncytial virus persistence in the lungs correlates with airway hyperreactivity in the mouse model.

Authors:  Dora Estripeaut; Juan Pablo Torres; Cynthia S Somers; Claudia Tagliabue; Shama Khokhar; Vijay G Bhoj; Steve M Grube; Aneta Wozniakowski; Ana M Gomez; Octavio Ramilo; Hasan S Jafri; Asuncion Mejias
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

8.  Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection.

Authors:  Taeg S Kim; Matthew M Hufford; Jie Sun; Yang-Xin Fu; Thomas J Braciale
Journal:  J Exp Med       Date:  2010-05-31       Impact factor: 14.307

9.  Use of a highly sensitive strand-specific quantitative PCR to identify abortive replication in the mouse model of respiratory syncytial virus disease.

Authors:  Richard Bannister; Deborah Rodrigues; Edward J Murray; Carl Laxton; Mike Westby; Helen Bright
Journal:  Virol J       Date:  2010-09-22       Impact factor: 4.099

10.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.